|Description||The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.|
|Related CAS||115104-28-4 (free acid)|
|Synonyms||sodium (E)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoate; MK-571; MK 571; MK571; MK-571 sodium salt; L-660,711; L660,711; L 660,711; L-660711; L660711; L 660711|
|Solubility||DMSO: ≥ 33 mg/mL|
|Application||The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
This active molecular is a selective LTD4 antagonist. CP-85958 may become a clinical candidates for the treatment of asthma in the future.
CP-195494, a benzothiazol derivative, was once studied as a leukotriene receptor antagonist.
KP496, a novel dual antagonist of cysLT receptor and TP, is currently in clinical development as a dry powder inhaler. KP496 inhibited epithelial hypertrophy an...
Cgp-35949 is an LTD4 antagonist which has phospholipase inhibitory activity. It represents a new approach to the treatment of asthma.
Acebilustat, formerly known as ZK322, is an oral anti-inflammatory designed to reduce the production of leukotriene B4 (LTB4),.
LY 210073, an oxoxanthene derivative, has been found to be a LTB4 receptor antagonist that could probably be effective against inflammation and rheumatic disord...
LY 245769 is a leukotriene E4 (LTE4) inhibitor, and it can inhibit the oxidative degradation of LTE4 and N-acetyl-LTE4 in animal model. LY 245769, as one of the...
This active molecular is a competitive leukotriene B4 receptor antagonist and IC50 value is about 100 nM. LY 255283 is selective for the BLT2 receptor, since IC...
CP-105696, a chromen derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied against sorts of nflammatory disease.
Cgp-33304 is a dual phospholipase A2 inhibiting agent and leukotriene receptor antagonists. It may prevent hypoxia secondary to leukotriene induced bronchoconst...
LY-306669, a tetrazol derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied its effect in acute lung injury.
LY 213024 is a potent leukotriene B4 receptor antagonist. Agents which block the production of the leukotrienes have shown reduction of infarct size in animal m...
Iralukast is a Leukotriene D4 receptor antagonist originated by Novartis as a a structural analogue of LTD4. It is applicated for the treatment of asthma and in...
FPL 55712 is a leukotriene receptor antagonist that inhibits contraction of guinea pig trachealis induced by leukotrienes C4, D4, E4 and F4.
WAY-126299A, a benzothiazoly derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist and was once studied in A...
ONO-4057 is a leukotriene B4 receptor antagonist originated by Ono Pharmaceutical. ONO-4057 is an Immunologic Factor and Immunosuppressive Agent. Clinical trial...
U66858, also known as Bunaprolast, is a hydroquinone inhibitor of leukotriene synthesis, which inhibits LTB4 production in human whole blood.
ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...
The sodium salt form of CP-199330 which is a chromen derivative and has been found to be a Leukotriene D4 receptor antagonist that was once studied against asth...
This active molecular is benzophenone dicarboxylic acid derivative which is a potent BLT1 receptor antagonist. It inhibits the binding of radiolabeled-LTB4 to i...